Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
As of today, Regeneron(REGN) shares are valued at $741.29. The company's market cap stands at 80.12B, with a P/E ratio of 17.88 and a dividend yield of 47.1%.
On 2025-12-12, Regeneron(REGN) stock traded between a low of $734.38 and a high of $747.65. Shares are currently priced at $741.29, which is +0.9% above the low and -0.9% below the high.
The Regeneron(REGN)'s current trading volume is 785.72K, compared to an average daily volume of 990.72K.
In the last year, Regeneron(REGN) shares hit a 52-week high of $790.98 and a 52-week low of $476.49.
In the last year, Regeneron(REGN) shares hit a 52-week high of $790.98 and a 52-week low of $476.49.
REGN News
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $768 from $767 and keeps an Equal Weight rating on the shares. The fi...
HSBC raised the firm’s price target on Regeneron (REGN) to $985 from $890 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. T...
Analyst ratings
67%
of 30 ratingsMore REGN News
Advertisement Market context and recent performance Regeneron Pharmaceuticals (REGN) has been drifting lower in the past week, even after a solid run over the...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adul...